drugset
Drugs / Iodine Povacrylex
last change Feb 2024 re-read 9 days ago

Iodine Povacrylex

also known as Iodine povacrylex component of duraprep

Other / unclassified

Investigated by
McMaster University · Patient-Centered Outcomes Research Institute · Universidad de El Salvador · University of Maryland, Baltimore

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) DURAPREP — 2006-09-29 fda.gov ↗

Trials 2

today
US approved 2006
NCT03859908 · Ph 4 NCT03523962 · Ph 4
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 42 trials
Phase 4 NCT03859908 Apr 2019 → Jan 2021 — Universidad de El Salvador Terminated No outcome recorded Stop: Enrollment
Phase 4 NCT03523962 Aug 2018 → Mar 2023 — University of Maryland, Baltimore Completed Mixed
Comparator or background therapy1 trial
— NCT01233050 Comparator Dec 2010 → Feb 2015 — University of Pennsylvania Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as iodine povacrylex “The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol.” NCT03523962 ↗
2

NCT01233050 ↗

NCT03859908 ↗
Known as Iodine povacrylex component of duraprep ChEMBL registry synonym — accepted as the source's own label CHEMBL1201721 ↗
Modality Other / unclassified “The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol.” NCT03523962 ↗
Route Topical “pre-operative skin preparation with an antiseptic solution” NCT03523962 ↗